Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus
Journal
Journal of Gastroenterology and Hepatology (Australia)
Journal Volume
31
Journal Issue
7
Pages
1323-1329
Date Issued
2016
Author(s)
Chuang W.-L.
Chien R.-N.
Peng C.-Y.
Chang T.-T.
Lo G.-H.
Sheen I.-S.
Wang H.-Y.
Chen J.-J.
Yang J.C.
Knox S.J.
Gao B.
Garrison K.L.
Mo H.
Pang P.S.
Hsu Y.-C.
Hu T.-H.
Chu C.-J.
Abstract
Background and Aim
Subjects
hepatitis C virus (HCV); infection; ledipasvir; sofosbuvir; Taiwan
SDGs
Other Subjects
glucose; hemoglobin A1c; ledipasvir plus sofosbuvir; benzimidazole derivative; carbamic acid derivative; drug combination; fluorene derivative; fused heterocyclic rings; ledipasvir; sofosbuvir; sofosbuvir-velpatasvir drug combination; tablet; adenomyosis; adult; aged; Article; cancer patient; chronic hepatitis C; compensated liver cirrhosis; coughing; dizziness; drug efficacy; drug safety; endometriosis; fatigue; female; glucose blood level; headache; hemoglobin blood level; Hepatitis C virus genotype 1; human; hyperglycemia; hyperkalemia; laboratory test; major clinical study; malaise; male; multicenter study; nausea; neutrophil count; open study; personal experience; phase 3 clinical trial; priority journal; rhinopharyngitis; side effect; small cell lung cancer; Taiwanese; treatment duration; treatment response; upper respiratory tract infection; clinical trial; drug combination; genetics; genotype; Hepacivirus; Hepatitis C, Chronic; middle aged; tablet; Taiwan; treatment outcome; virology; Adult; Aged; Benzimidazoles; Carbamates; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Sofosbuvir; Tablets; Taiwan; Treatment Outcome
Publisher
Blackwell Publishing
Type
journal article